Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly
ADP Ribose Transferases
Models, Molecular
0301 basic medicine
Binding Sites
Clostridioides difficile
Protein Conformation
Bacterial Toxins
Cryoelectron Microscopy
Biological Sciences
Crystallography, X-Ray
Biophysical Phenomena
3. Good health
Enterotoxins
03 medical and health sciences
Bacterial Proteins
Protein Domains
Chlorocebus aethiops
Animals
Nuclear Magnetic Resonance, Biomolecular
Vero Cells
DOI:
10.1073/pnas.1919490117
Publication Date:
2020-01-03T01:05:55Z
AUTHORS (25)
ABSTRACT
Targeting
Clostridium difficile
infection is challenging because treatment options are limited, and high recurrence rates are common. One reason for this is that hypervirulent
C. difficile
strains often have a binary toxin termed the
C. difficile
toxin, in addition to the enterotoxins TsdA and TsdB. The
C. difficile
toxin has an enzymatic component, termed CDTa, and a pore-forming or delivery subunit termed CDTb. CDTb was characterized here using a combination of single-particle cryoelectron microscopy, X-ray crystallography, NMR, and other biophysical methods. In the absence of CDTa, 2 di-heptamer structures for activated CDTb (1.0 MDa) were solved at atomic resolution, including a symmetric (
Sym
CDTb; 3.14 Å) and an asymmetric form (
Asym
CDTb; 2.84 Å). Roles played by 2 receptor-binding domains of activated CDTb were of particular interest since the receptor-binding domain 1 lacks sequence homology to any other known toxin, and the receptor-binding domain 2 is completely absent in other well-studied heptameric toxins (i.e., anthrax). For
Asym
CDTb, a Ca
2+
binding site was discovered in the first receptor-binding domain that is important for its stability, and the second receptor-binding domain was found to be critical for host cell toxicity and the di-heptamer fold for both forms of activated CDTb. Together, these studies represent a starting point for developing structure-based drug-design strategies to target the most severe strains of
C. difficile
.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (62)
CITATIONS (28)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....